Ptc Therapeutics (PTCT) Total Debt (2016 - 2025)
Ptc Therapeutics has reported Total Debt over the past 14 years, most recently at $286.6 million for Q4 2025.
- Quarterly results put Total Debt at $286.6 million for Q4 2025, down 47.24% from a year ago — trailing twelve months through Dec 2025 was $286.6 million (down 47.24% YoY), and the annual figure for FY2025 was $286.6 million, down 47.24%.
- Total Debt for Q4 2025 was $286.6 million at Ptc Therapeutics, roughly flat from $286.3 million in the prior quarter.
- Over the last five years, Total Debt for PTCT hit a ceiling of $679.0 million in Q3 2023 and a floor of $286.3 million in Q3 2025.
- Median Total Debt over the past 5 years was $495.1 million (2023), compared with a mean of $481.2 million.
- Biggest five-year swings in Total Debt: surged 90.27% in 2023 and later crashed 47.24% in 2025.
- Ptc Therapeutics' Total Debt stood at $341.2 million in 2021, then surged by 88.72% to $643.9 million in 2022, then dropped by 25.68% to $478.5 million in 2023, then grew by 13.52% to $543.2 million in 2024, then crashed by 47.24% to $286.6 million in 2025.
- The last three reported values for Total Debt were $286.6 million (Q4 2025), $286.3 million (Q3 2025), and $548.0 million (Q2 2025) per Business Quant data.